Abstract
Although most patients with epithelial ovarian cancer will present with International Federation of Gynecology and Obstetrics (FIGO) stage III or IV disease, occasionally, a woman with a pelvic mass in the absence of ascites, carcinomatosis, and pleural effusion or other clinical and radiologic findings of advanced disease will be ultimately diagnosed with an early stage ovarian carcinoma (Figure 3.1).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
American College of Obstetricians and Gynecologists. ACOG Committee Opinion: Number 280, December 2002. The role of the generalist obstetrician-gynecologist in the early detection of ovarian cancer. Obstet Gynecol. 2002;100:1413-1416.
Zhu CS, Pinsky PF, Cramer DW, et al. A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. Cancer Prev Res (Phila). 2011;4:375-383.
Miller RW, Smith A, DeSimone COP, et al. Performance of the American College of Obstetricians and Gynecolgists’ ovarian tumor referral guidelines with a multivariate index assay. Obstet Gynecol. 2011;117:1-9.
Ueland FR, Desimone CP, Seamon LG, et al. Effectiveness of a multivariate index assayin the preoperative assessment of ovarian tumors. Obstet Gynecol. 2011;117:1289-1297.
Bristow RE, Smith A, Zhang Z, et al. Ovarian malignancy risk stratification of the adnexal mass using a multivariate index assay. Gynecol Oncol. 2013;128:252-259.
Hellstrom I, Raycraft J, Hayden-Ledbetter M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 2003;63:3695-3700.
Moore RG, Brown AK, Miller C, et al. The use of multiple novel serum biomarkers for the detection of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2008;108;402-408.
Moore RG, McMeekin DC, Brown AK, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2009;112:40-46.
Moore RG, Miller C, Disilvestro P, et al. Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass. Obstet Gynecol. 2011;118:280‑288.
Coleman RL, Monk BJ, Sood AK, Herzog TJ. Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol. 2013;10:211-224.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Tewari, K., Monk, B. (2015). Clinical presentation and diagnostics. In: The 21st Century Handbook of Clinical Ovarian Cancer. Adis, Cham. https://doi.org/10.1007/978-3-319-08066-6_3
Download citation
DOI: https://doi.org/10.1007/978-3-319-08066-6_3
Published:
Publisher Name: Adis, Cham
Print ISBN: 978-3-319-08065-9
Online ISBN: 978-3-319-08066-6
eBook Packages: MedicineMedicine (R0)